Due: November 20, 2025
The purpose of this RPP is to support the advanced development, clinical evaluation, and FDA clearance of mNGS-based diagnostic assays for viral and bacterial pathogen detection. BARDA seeks highly flexible, rapidly adaptable systems capable of identifying all known viral and bacterial pathogens within a given specimen (e.g., respiratory sample) and reconfiguring-through database or software updates—to detect emerging pathogens during public health emergencies. BARDA requires the use of existing mNGS-based sequencing platforms or mNGS platforms that are already in development. Both laboratory and point-of-care mNGS solutions are sought.
This opportunity requires membership in the Rapid Response Partnership Vehicle (RRPV). This Consortium releases numerous opportunities throughout the year, so even if this one may not be right for you, we strongly encourage you to join the consortium, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.